L. Ii/-place-de-la-tep-À-la-18f-fdopa-dans,

. .. Ii.1-principe-de-la-tep-À-la-18f-fdopa, 3 Protocole d'acquisition d'une TEP à la 18F-FDOPA

A. and .. .. , 6 Sécrétion de catécholamines et intensité de captation de la 18F-FDOPA : une corrélation ?

J. W. Lenders, Q. Y. Duh, G. Eisenhofer, A. P. Gimenez-roqueplo, S. K. Grebe et al., Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.6, pp.1915-1942, 2014.

E. Baudin, M. A. Habra, F. Deschamps, G. Cote, F. Dumont et al., THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma, European Journal of Endocrinology, vol.171, issue.3, pp.R111-R122, 2014.

V. Laboureau-s-&-rohmer and . Phéochromocytome,

N. Burnichon, A. Buffet, and A. P. Gimenez-roqueplo, Pheochromocytoma and paraganglioma, Current Opinion in Oncology, vol.28, issue.1, pp.5-10, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01048691

J. Favier, L. Amar, and A. P. Gimenez-roqueplo, Paraganglioma and phaeochromocytoma: from genetics to personalized medicine, Nature Reviews Endocrinology, vol.11, issue.2, pp.101-111, 2014.

A. P. Gimenez-roqueplo, J. Favier, R. P. Rieubland, C. Crespin, M. Nau et al., Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas, Cancer Research, vol.63, pp.5615-5621, 2003.

R. F. Stolk, C. Bakx, J. Mulder, H. J. Timmers, and J. W. Lenders, Is the Excess Cardiovascular Morbidity in Pheochromocytoma Related to Blood Pressure or to Catecholamines?, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.3, pp.1100-1106, 2013.

G. Eisenhofer, H. Keiser, P. Friberg, E. Mezey, T. T. Huynh et al., Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol-O-Methyltransferase Within Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.83, issue.6, pp.2175-2185, 1998.

H. J. Timmers, K. Pacak, T. T. Huynh, M. Abu-asab, M. Tsokos et al., Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in theSuccinate Dehydrogenase Subunit BGene, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.12, pp.4826-4832, 2008.

. Herbomez-m-d', C. Cao, . Do, D. Vezzosi, F. Borzon-chasot et al., Chromogranin A assay in clinical practice, Annales d'Endocrinologie, vol.71, pp.274-280, 2010.

I. Ilias, A. Sahdev, R. H. Reznek, A. B. Grossman, and K. Pacak, The optimal imaging of adrenal tumours: a comparison of different methods, Endocrine Related Cancer, vol.14, issue.3, pp.587-599, 2007.

A. P. Gimenez-roqueplo, A. Caumont-prim, C. Houzard, C. Hignette, A. Hernigou et al., Imaging Work-Up for Screening of Paraganglioma and Pheochromocytoma inSDHxMutation Carriers: A Multicenter Prospective Study from the PGL.EVA Investigators, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.1, pp.E162-E173, 2013.

D. Taïeb, H. J. Timmers, E. Hindié, B. A. Guillet, H. P. Neumann et al., EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma, European Journal of Nuclear Medicine and Molecular Imaging, vol.39, issue.12, pp.1977-1995, 2012.

F. Castinetti, A. Kroiss, R. Kumar, K. Pacak, and D. Taieb, 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma, Endocrine-Related Cancer, vol.22, issue.4, pp.T135-T145, 2015.

L. Thompson, Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms, The American Journal of Surgical Pathology, vol.26, issue.5, pp.551-566, 2002.

P. A. Zee, . Van, A. Boer, and . De, Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin, The Netherlands Journal of Medicine, 0201.

F. Castinetti, D. Taieb, J. F. Henry, M. Walz, C. Guerin et al., MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma, European Journal of Endocrinology, vol.174, issue.1, pp.R9-R18, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01473972

M. Ayala-ramirez, C. N. Chougnet, M. A. Habra, J. L. Palmer, S. Leboulleux et al., Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.11, pp.4040-4050, 2012.

. Dreuille-o-de, P. Maszelin, H. Foehrenbach, G. Bonardel, and J. F. Gaillard, Principe et technique de la tomographie par émission de positons (TEP), 200412.

P. L. Jager, R. Chirakal, C. J. Marriott, A. H. Brouwers, K. P. Koopmans et al., 6-L-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications, Journal of Nuclear Medicine, vol.49, issue.4, pp.573-586, 2008.

M. Soussan, V. Nataf, K. Kerrou, D. Grahek, O. Pascal et al., Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer, Nuclear Medicine Communications, vol.33, issue.7, pp.775-779, 2012.

H. J. Timmers, M. Hadi, J. A. Carrasquillo, C. C. Chen, L. Martiniova et al., The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma, Journal of Nuclear Medicine, vol.48, issue.10, pp.1599-1606, 2007.

S. Chondrogiannis, M. Cristina-marzola, A. Al-nahhas, T. D. Venkatanarayana, A. Mazza et al., Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging, Nuclear Medicine Communications, vol.34, issue.12, pp.1141-1149, 2013.

(. Huang, . Henry, and . Sung-cheng, Anatomy of SUV, Nuclear Medicine and Biology, vol.27, issue.7, pp.643-646, 2000.

A. Berkowitz, S. Basu, S. Srinivas, S. Sankaran, S. Schuster et al., Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET, Nuclear Medicine Communications, vol.29, issue.6, pp.521-526, 2008.

G. Treglia, F. Cocciolillo, C. Waure, . De, F. D. Nardo et al., Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis, European Journal of Nuclear Medicine and Molecular Imaging, vol.2012, pp.39-1144

D. Taïeb, L. Tessonnier, F. Sebag, P. Niccoli-sire, I. Morange et al., The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas, Clinical Endocrinology, pp.69-580, 2008.

G. Agarwal, D. Sadacharan, A. Kapoor, A. Batra, P. Dabadghao et al., Cardiovascular dysfunction and catecholamine cardiomyopathy in pheochromocytoma patients and their reversal following surgical cure: Results of a prospective case-control study, Surgery, vol.150, issue.6, pp.1202-1211, 2011.

A. Verma, A. K. Mishra, S. K. Duh, Q. Y. Eisenhofer, G. Gimenez-roqueplo et al., Cardiovascular dysfunction and catecholamine cardiomyopathy in pheochromocytoma patients and their reversal following surgical cure: results of a prospective casecontrol study, Surgery, vol.150, pp.1202-1211, 2011.

M. Naruse, K. Pacak, W. F. Young, and P. Pheochromocytoma, An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 1915.

J. Favier, L. Amar, and A. P. Gimenez-roqueplo, Paraganglioma and phaeochromocytoma: from genetics to personalized medicine, Nature Reviews Endocrinology, vol.11, issue.2, pp.101-111, 2014.

D. Taïeb, H. J. Timmers, E. Hindié, B. A. Guillet, H. P. Neumann et al., guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma, European Journal of Nuclear Medicine and Molecular Imaging, 1977.

F. Castinetti, A. Kroiss, R. Kumar, K. Pacak, and D. Taieb, 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma, Endocrine-Related Cancer, vol.22, issue.4, pp.T135-T145, 2015.

P. L. Jager, R. Chirakal, C. J. Marriott, A. H. Brouwers, K. P. Koopmans et al., 6-L-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications, Journal of Nuclear Medicine, vol.49, issue.4, pp.573-586, 2008.

. 18f-fluorodihydroxyphenylalanine, Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications, pp.49-573, 2008.

V. Amodru, C. Guerin, S. Delcourt, P. Romanet, A. Loundou et al., Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.2, pp.278-282, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01876274

F. Sebag, K. Pacak, and D. Taïeb, Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype, European Journal of Nuclear Medicine and Molecular Imaging, 2005.
URL : https://hal.archives-ouvertes.fr/hal-01876274

E. V. Mosharov and D. Sulzer, Analysis of exocytotic events recorded by amperometry, Nature Methods, vol.2, issue.9, pp.651-658, 2005.

G. Eisenhofer, J. W. Lenders, D. S. Goldstein, M. Mannelli, G. Csako et al., Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines, Clinical Chemistry, vol.51, issue.4, pp.735-744, 2005.

&. Fm and K. Pacak, Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines, Clinical Chemistry, pp.51-735, 2005.

L. Thompson, Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to

L. D. Thompson, Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms, The American Journal of Surgical Pathology, vol.26, issue.5, pp.551-566, 2002.

A. Berkowitz, S. Basu, S. Srinivas, S. Sankaran, S. Schuster et al., Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET, Nuclear Medicine Communications, vol.29, issue.6, pp.521-526, 2008.

S. Houy, C. Estay-ahumada, P. Croise, V. Calco, A. Haeberle et al., Oligophrenin-1 Connects Exocytotic Fusion to Compensatory Endocytosis in Neuroendocrine Cells, Journal of Neuroscience, vol.35, issue.31, pp.11045-11055, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02323341

M. F. Bader, S. Ory, and S. Gasman, Oligophrenin-1 Connects Exocytotic Fusion to Compensatory Endocytosis in Neuroendocrine Cells, The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, vol.35, pp.11045-11055, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02323341

F. Segura, M. A. Brioso, J. F. Gómez, J. D. Machado, and R. Borges, Automatic analysis for amperometrical recordings of exocytosis, Journal of Neuroscience Methods, vol.103, issue.2, pp.151-156, 2000.

G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi et al., The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management, Endocrine Reviews, vol.25, issue.2, pp.309-340, 2004.

A. Humbert, G. Lecoanet, S. Moog, F. Bouderraoui, L. Bresler et al., The computed tomography adrenal wash-out analysis properly classifies cortisol secreting adrenocortical adenomas, Endocrine, vol.59, issue.3, pp.529-537, 2018.

H. B. Fiebrich, A. H. Brouwers, M. N. Kerstens, M. E. Pijl, I. P. Kema et al., 6-[F-18]Fluoro-l-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.10, pp.3922-3930, 2009.

. Fluoro-l-dihydroxyphenylalanine, Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess, The Journal of Clinical Endocrinology & Metabolism, vol.94, pp.3922-3930, 2009.

F. Imani, V. G. Agopian, M. S. Auerbach, M. A. Walter, F. Imani et al., 18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas, Journal of Nuclear Medicine, vol.50, issue.4, pp.513-519, 2009.

R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma, Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study, Journal of Nuclear Medicine, vol.45, pp.1519-1527, 2004.

J. W. Keyes, SUV: standard uptake or silly useless value, Journal of Nuclear Medicine, vol.36, pp.1836-1839, 1995.

C. Guerin, F. Pattou, L. Brunaud, J. C. Lifante, E. Mirallié et al., Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.102, issue.7, pp.2465-2472, 2017.

C. Houzard, C. Ansquer, E. Hindié, A. Loundou, C. Archange et al.,

D. Taïeb, Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.102, pp.2465-2472, 2017.

L. Groussin, G. Bonardel, S. Silve?ra, F. Tissier, J. Coste et al., 18F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, pp.1713-1722, 2009.

H. Bertagna, X. Tenenbaum, and F. 18f-fluorodeoxyglucose, Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients, The Journal of Clinical Endocrinology & Metabolism, vol.94, pp.1713-1722, 2009.

L. M. Weiss, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors, The American Journal of Surgical Pathology, vol.8, issue.3, pp.163-170, 1984.

H. H. Verbeek, J. T. Plukker, K. P. Koopmans, J. W. De-groot, R. M. Hofstra et al., Clinical Relevance of 18F-FDG PET and 18F-DOPA PET in Recurrent Medullary Thyroid Carcinoma, Journal of Nuclear Medicine, vol.53, issue.12, pp.1863-1871, 2012.

H. B. Fiebrich, J. R. De-jong, I. P. Kema, K. P. Koopmans, W. Sluiter et al., Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour, European Journal of Nuclear Medicine and Molecular Imaging, vol.38, issue.10, pp.1854-1861, 2011.

M. Haissaguerre, M. Courel, P. Caron, S. Denost, C. Dubessy et al., Normotensive Incidentally Discovered Pheochromocytomas Display Specific Biochemical, Cellular, and Molecular Characteristics, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.11, pp.4346-4354, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01706417

G. Belleannée, M. L. Jullié, M. Montero-hadjadje, Y. L. Corcuff, J. B. Fagour et al., Normotensive Incidentally Discovered Pheochromocytomas Display Specific Biochemical, Cellular, and Molecular Characteristics, The Journal of Clinical Endocrinology & Metabolism, pp.98-4346, 2013.

A. Riester, D. Weismann, M. Quinkler, U. D. Lichtenauer, S. Sommerey et al., Life-threatening events in patients with pheochromocytoma, European Journal of Endocrinology, vol.173, issue.6, pp.757-764, 2015.

R. Spitzweg, C. Schopohl, J. Beuschlein, F. Reincke, and M. , Life-threatening events in patients with pheochromocytoma, European Journal of Endocrinology, pp.173-757, 2015.

N. Reisch, M. Peczkowska, A. Januszewicz, and H. Neumann, Pheochromocytoma: presentation, diagnosis and treatment, Journal of Hypertension, 2331.

V. Amodru, C. Guerin, S. Delcourt, P. Romanet, A. Loundou et al., Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype, European Journal of Nuclear Medicine and Molecular Imaging, 2005.
URL : https://hal.archives-ouvertes.fr/hal-01876274

F. Imani, V. G. Agopian, M. S. Auerbach, M. A. Walter, F. Imani et al., 18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas, Journal of Nuclear Medicine, vol.50, issue.4, pp.513-519, 2009.

H. B. Fiebrich, A. H. Brouwers, M. N. Kerstens, M. E. Pijl, I. P. Kema et al., 6-[F-18]Fluoro-l-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.10, pp.3922-3930, 2009.

. Fluoro-l-dihydroxyphenylalanine, Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess, The Journal of Clinical Endocrinology & Metabolism, vol.94, pp.3922-3930, 2009.

R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma, Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study, Journal of Nuclear Medicine, vol.45, pp.1519-1527, 2004.

A. L. Humbert, G. Lecoanet, S. Moog, F. Bouderraoui, L. Bresler et al., The computed tomography adrenal wash-out analysis properly classifies cortisol secreting adrenocortical adenomas, Endocrine, vol.59, issue.3, pp.529-537, 2018.

C. Guerin, F. Pattou, L. Brunaud, J. C. Lifante, E. Mirallié et al., Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.102, issue.7, pp.2465-2472, 2017.

L. Groussin, G. Bonardel, S. Silve?ra, F. Tissier, J. Coste et al., 18F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, pp.1713-1722, 2009.

L. M. Weiss, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors, The American Journal of Surgical Pathology, vol.8, issue.3, pp.163-170, 1984.

B. J. Fueger, J. Czernin, T. Cloughesy, D. H. Silverman, C. L. Geist et al., Correlation of 6-18F-Fluoro-l-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas, Journal of Nuclear Medicine, vol.51, pp.1532-1538, 2010.

H. B. Fiebrich, J. R. De-jong, I. P. Kema, K. P. Koopmans, W. Sluiter et al., Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour, European Journal of Nuclear Medicine and Molecular Imaging, vol.38, issue.10, pp.1854-1861, 2011.

H. H. Verbeek, J. T. Plukker, K. P. Koopmans, J. W. De-groot, R. M. Hofstra et al., Clinical Relevance of 18F-FDG PET and 18F-DOPA PET in Recurrent Medullary Thyroid Carcinoma, Journal of Nuclear Medicine, vol.53, issue.12, pp.1863-1871, 2012.

M. Haissaguerre, M. Courel, P. Caron, S. Denost, C. Dubessy et al., Normotensive Incidentally Discovered Pheochromocytomas Display Specific Biochemical, Cellular, and Molecular Characteristics, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.11, pp.4346-4354, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01706417

E. V. Mosharov and D. Sulzer, Analysis of exocytotic events recorded by amperometry, Nature Methods, vol.2, issue.9, pp.651-658, 2005.

F. Castinetti, A. Kroiss, R. Kumar, K. Pacak, and D. Taieb, 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma, Endocrine-Related Cancer, vol.22, issue.4, pp.T135-T145, 2015.

*. Résumé&amp;de&amp;la&amp;thèse&amp;-&amp;-introduction&amp;, :. Le*-phéochromocytome, and *. Pheo)*-est*-une*-tumeur*-neuroendocrine*-rare*-dont*-l&apos;hypersécrétion*-de*-catécholamines*-peut*-entraîner*-une*-morbidité*-importante*-par*-le*-biais*-des*-complications*cardiovasculaires*qu&apos;elle*engendre, Carte des Îles de Pong-hou suivant le point sur le quel ont été faites les Cartes de la Chine et de la Tartarie par l'Ordre et aux frais de l'Empereur, * aux*taux*de*NM*urinaires*(r=0.64,*p<0.0001,*n=36)*et*de*MN*urinaires*(r=0.49,*p=0.002,*n=35)*ainsi* qu'aux*taux*de*NM*plasmatiques*(r=0.55*p=0.006,*n=23)*et*de*CGA*(r=0.61,*p=0.0005,*n=28).*Les* paramètres*SUVs*(SUVmoyen,*SUVmax)*sont*quant*à*eux*uniquement*corrélés*avec*la*CGA*

*. *en*analyse*ampérométrique,*une*corrélation*positive*est*observée*entre*le*ratio*suvmax, ;. Pheo*-/*-suvmax*-hépatique*-et*-le*-nombre*-de, and . Année, * pics* par* cellule* obtenu* pour* chaque* tumeur* (r=1,* p=0,01).** Conclusion& :* Le* MB* est* un* outil* important* pour* la* détermination* de* la* sécrétion* hormonale* des* phéochromocytomes*en*TEP/TDM.*L'augmentation*de*l'activité*de*l'exocytose*au*niveau*cellulaire* semble*favoriser*la*captation*de* 18 F^FDOPA.* & TITRE&EN&ANGLAIS&:&DOES* 18, 2018.

. ********9 and . Forêt*de*haye,

*. Vandoeuvre*les*nancy*cedex,